EHA 2023 | Identifying patients with CLL at a high risk of developing cardiotoxicity with BTK inhibitors

Farrukh Awan, MD, UT Southwestern Medical Center, Dallas, TX, discusses the cardiac side effects associated with treatment with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL). Dr Awan explains that the key side effects associated with first-generation BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib are atrial fibrillation, hypertension, ventricular arrhythmia, and sudden cardiac death. Dr Awan notes the importance of conducting a comprehensive baseline cardiac evaluation in all patients before treatment with BTK inhibitors to provide additional care to patients at a higher risk of developing cardiotoxicity. Dr Awan also notes that choosing between different BTK inhibitors in the future will be mostly based on toxicity as efficacy seems to be comparable between the different BTK inhibitors. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.